Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Phase 3]
A Phase 3 trial of SGX301 (synthetic hypericin) topical treatment for cutaneous T-cell lymphoma (mycosis fungoides) has completed with poste…
-
CLINICAL_TRIALS trial_result · 2022-04-08Clinical Trial Update: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating Cobomarsen (MRG-106) versus an active comparator in Mycosis Fungoides, a form of Cutaneous T-Cell Lymphoma; study t…
-
CLINICAL_TRIALS trial_result · 2022-01-25Clinical Trial Update: TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides [Phase 3]
A Phase 3 trial evaluating total skin electron beam therapy (low-dose) for eradicating tumor clones in early-stage mycosis fungoides (cutane…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Mechlorethamine Induced Contact Dermatitis Avoidance Study [Phase 2]
Phase 2 clinical trial assessing avoidance of mechlorethamine–induced contact dermatitis in patients with cutaneous T-cell lymphoma.
-
FDA approval · 2021-10-12FDA Approved: ROMIDEPSIN — Original Application (Fresenius Kabi USA, LLC)
FDA approved the original ANDA for romidepsin by Fresenius Kabi USA, LLC, providing a generic version of the cancer therapy for certain T-ce…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial of oral LBH589 (panobinostat) in adults with refractory cutaneous T-cell lymphoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma has completed rec…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 study of oral LBH589 in adults with refractory/resistant cutaneous T-cell lymphoma (CTCL) was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL [Phase 1, Phase 2]
A dose-ranging study of IV BNZ-1 in LGL Leukemia or refractory cutaneous T-cell lymphoma (CTCL) has completed Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 trial update for CD11301 in Cutaneous T-Cell Lymphoma (CTCL) assessing safety, efficacy, and pharmacokinetics.
-
FDA label_change · 2021-03-24FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Istodax (romidepsin) to update its labeling, likely reflecting a new indication, safety, or othe…
-
FDA approval · 2021-03-19FDA Approved: UVADEX — Supplemental Application (Therakos LLC)
FDA approved a supplemental application for UVADEX (methoxsalen) from Therakos LLC.
-
FDA approval · 2021-01-14FDA Approved: BEXAROTENE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s original application for generic Bexarotene. The drug is indicated for the treatment of cutaneous T-cell…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 [Phase 2]
Phase 2 extension study of mogamulizumab (KW-0761) for Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma in patients who relapsed aft…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating allogeneic transplantation in patients with cutaneous T-cell lymphoma has completed with results posted.
-
FDA approval · 2020-11-23FDA Approved: BEXAROTENE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Bexarotene from ANI Pharmaceuticals, updating the labeling for this product.
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib/dexamethasone therapy in relapsed/refractory cutaneous T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 study in participants with relapsed cutaneous T-cell lymphoma has completed with results posted.
-
FDA approval · 2020-05-01FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for Valchlor (mechlorethamine hydrochloride) filed by Helsinn Therapeutics (U.S.), Inc. This act…
-
CLINICAL_TRIALS trial_result · 2020-03-05Clinical Trial Update: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study [Phase 2]
A multicenter Phase II trial evaluating sintilimab plus chidamide for relapsed and refractory cutaneous T-cell lymphoma.
-
FDA label_change · 2020-01-13FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approves a supplemental application for VALCHLOR (mechlorethamine hydrochloride) to expand its labeling for the topical treatment of cut…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma [Phase 1]
Phase 1 trial assessing safety and efficacy of a dual PI3K Delta/Gamma inhibitor in T-cell lymphoma types; study completed with posted resul…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) [Phase 4]
A Phase 4 trial evaluating two dose levels of Targretin capsules in participants with refractory cutaneous T-cell lymphoma has completed wit…
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma [Phase 1]
A Phase 1 dose-escalation study evaluating carfilzomib with and without romidepsin in cutaneous T-cell lymphoma (CTCL) was terminated with r…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating topical resiquimod for early stage cutaneous T cell lymphoma (CTCL) has completed with results posted in…